Business
IDEAYA Biosciences CEO Yujiro Hata Says First NDA Filed, Darovasertib Approval Possible in 2027
By News Desk ·
Key takeaways
- IDEAYA Biosciences filed its first NDA and reported top-line results in an oral presentation at ASCO, CEO Yujiro Hata said at the UBS Global Biopharma Conference.
- UBS analyst Michael Yee said darovasertib for metastatic uveal melanoma could receive potential approval in 2027.
- IDEAYA closed a $345 million underwritten public offering in June 2026 and reported about $1.05 billion in cash as of December 31, 2025.
IDEAYA Biosciences has filed its first new drug application and reported top-line results in an oral presentation at ASCO, CEO Yujiro Hata said at the UBS Global Biopharma Conference on November 16, 2026. Seeking Alpha published the transcript of the session.
Hata Outlines First NDA and Darovasertib Timeline
Hata, founder, president, CEO and chairman of IDEAYA Biosciences, described 2026 as a transformational year for the company. He said IDEAYA filed its first NDA and reported top-line results in an oral presentation at ASCO several months earlier.
UBS senior biotechnology analyst Michael Yee, who hosted the session, said darovasertib for metastatic uveal melanoma is a small molecule with positive Phase III results and that potential approval may come in 2027. "That may happen in 2027 on the brink of your first approval," Yee said. Hata thanked Yee for hosting and congratulated UBS Investment Bank on its inaugural event in London that week.
IDEAYA Biosciences is a clinical-stage precision medicine oncology company developing targeted small molecules and antibody-drug conjugates for genetically defined solid tumors, with darovasertib in uveal melanoma under FDA review.
Funding and Cash Position Behind the Registrational Push
According to akta.pro company records, IDEAYA closed a $345 million underwritten public offering in June 2026, comprising 7,222,225 shares at $27.00 plus pre-funded warrants, to fund registrational and clinical programs and extend its cash runway into 2030. The company reported approximately $1.05 billion in cash, cash equivalents and marketable securities as of December 31, 2025.
The same records show the FDA accepted IDEAYA's NDA for darovasertib plus crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma under the Real-Time Oncology Review program, with potential accelerated approval targeted for the second half of 2026.
Earlier Data and Leadership Changes
In October 2026, IDEAYA Biosciences and Servier presented updated data from three darovasertib trials in uveal melanoma at ESMO, covering metastatic and primary disease, The Pharma Letter reported. The company moved Dr. Michael White from Chief Scientific Officer to President, R&D, effective September 28, 2026, Yahoo reported.
IDEAYA reported third-quarter 2026 revenue of $10.24 million and a net loss of $125.75 million, compared with $207.83 million in revenue and $119.24 million in net income a year earlier, Simply Wall St reported.
R&D Day in London
IDEAYA Biosciences will participate in investor events in London on November 16 and 17, 2026, including an Investor R&D Day, Stock Titan reported. Yee said at the conference that IDEAYA was hosting an R&D analyst event later that day.